The Efficacy and Safety of Daratumumab-Based Combination Therapy in Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2025.03.027
- Author:
Fan GAO
1
;
Yu-Lan ZHOU
1
;
Shi-Xuan WANG
1
;
Hui-Min SHEN
1
;
Min YU
1
;
Fei LI
1
Author Information
1. Department of Hematology, The First Affiliated Hospital of Nanchang University; Institute of Hematology, Academy of Clinical Medicine of Jiangxi Province; Institute of Lymphoma of Nanchang University, Nanchang 330006, Jiangxi Province, China.
- Publication Type:Journal Article
- Keywords:
daratumumab;
multiple myeloma;
efficacy;
safety;
real-world research
- MeSH:
Humans;
Multiple Myeloma/drug therapy*;
Middle Aged;
Aged;
Male;
Female;
Antibodies, Monoclonal/administration & dosage*;
Adult;
Retrospective Studies;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*;
Treatment Outcome
- From:
Journal of Experimental Hematology
2025;33(3):810-815
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the efficacy and safety of combination regimen containing daratumumab in multiple myeloma (MM) patients.
METHODS:The clinical data of 14 newly diagnosed MM patients and 58 relapsed refractory MM patients treated with combination regimen containing daratumumab from November 2020 to March 2023 in the First Affiliated Hospital of Nanchang University were retrospectively analyzed. The efficacy and safety of combination regimen were analyzed.
RESULTS:The median age of the 72 patients was 62 (38-78) years, including 35 males and 37 females. The overall response rate (ORR) of patients receiving first-line, second-line, and third-line or above treatment was 92.9% (13/14), 68.2% (30/44), and 42.9% (6/14), respectively. The median progression-free survival (PFS) was not reached, 15.4 months, and 9.7 months in three groups, respectively (all P <0.05), while the median overall survival (OS) was all not reached. Among relapsed refractory patients, the ORR of those treated with DVd, DPd and DRd regimen was 50.0% (12/24), 40.0% (4/10) and 100% (10/10), the median PFS was 2.8 months, 10.3 months and not reached, and the median OS was 15.4 months, not reached and not reached, respectively. Furthermore, the PFS and OS in the DRd group were superior to those in the other two groups (all P <0.05). Cox univariate and multivariate analysis showed that lactate dehydrogenase (LDH) ≥250 U/L and extramedullary disease were independent adverse prognostic factors for PFS, and LDH ≥250 U/L was also an independent adverse prognostic factor for OS. Hematologic adverse reactions were mainly lymphopenia (87.5%) and thrombocytopenia (52.8%), while non-hematologic adverse reactions were mainly infusion-related reactions (19.4%) and infections (11.1%).
CONCLUSIONS:The combination regimens containing daratumumab can be used as first-line treatment for patients with newly diagnosed MM. In patients with relapsed refractory MM, early use of regimens containing daratumumab may improve treatment response rate and prolong PFS. The DRd regimen has better therapeutic response and survival advantages. LDH is an independent prognostic factor affecting PFS and OS in MM patients.
